The calcitonin gene-related peptide (CGRP) inhibitor galcanezumab (Emgality) will be PBS listed for the treatment of chronic migraine from June 1. The long-awaited PBS listing was part of the Federal Government’s Budget 2021-22 announcement which included $43 billion allocated over four years to the PBS. Neurologist Associate Professor Richard Stark, from the Alfred Hospital, welcomed ...
Milestone as first CGRP inhibitor listed on the PBS for chronic migraine
By Mardi Chapman
13 May 2021